Compare Stocks: SRPT, OPHLF, BHC, and IONS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BHC Bausch Health Cos	$6.49 +0.5%	$6.18	$4.33 ▼ $8.00	$2.41B	0.37	1.84 million shs	1.20 million shs
IONS Ionis Pharmaceuticals	$43.91 -0.8%	$50.82	$42.08 ▼ $86.74	$7.36B	0.38	3.12 million shs	5.01 million shs
OPHLF Ono Pharmaceutical	$15.16	$15.12	$11.08 ▼ $18.67	$7.12B	0.38	109 shs	N/A
SRPT Sarepta Therapeutics	$18.18 -2.0%	$19.32	$14.68 ▼ $24.68	$1.96B	0.38	3.07 million shs	1.24 million shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BHC Bausch Health Cos	+0.46%	+2.69%	+11.71%	+46.55%	+3.93%
IONS Ionis Pharmaceuticals	-0.81%	-0.48%	-4.02%	-22.35%	-38.59%
OPHLF Ono Pharmaceutical	0.00%	+1.40%	+7.14%	+3.76%	+28.31%
SRPT Sarepta Therapeutics	-2.05%	+2.19%	-12.64%	+15.94%	-19.09%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BHC Bausch Health Cos	$6.49 +0.5%	$6.18	$4.33 ▼ $8.00	$2.41B	0.37	1.84 million shs	1.20 million shs
IONS Ionis Pharmaceuticals	$43.91 -0.8%	$50.82	$42.08 ▼ $86.74	$7.36B	0.38	3.12 million shs	5.01 million shs
OPHLF Ono Pharmaceutical	$15.16	$15.12	$11.08 ▼ $18.67	$7.12B	0.38	109 shs	N/A
SRPT Sarepta Therapeutics	$18.18 -2.0%	$19.32	$14.68 ▼ $24.68	$1.96B	0.38	3.07 million shs	1.24 million shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BHC Bausch Health Cos	+0.46%	+2.69%	+11.71%	+46.55%	+3.93%
IONS Ionis Pharmaceuticals	-0.81%	-0.48%	-4.02%	-22.35%	-38.59%
OPHLF Ono Pharmaceutical	0.00%	+1.40%	+7.14%	+3.76%	+28.31%
SRPT Sarepta Therapeutics	-2.05%	+2.19%	-12.64%	+15.94%	-19.09%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BHC Bausch Health Cos	2.14	Hold	$8.00	23.36% Upside
IONS Ionis Pharmaceuticals	2.78	Moderate Buy	$89.48	103.77% Upside
OPHLF Ono Pharmaceutical	2.00	Hold	N/A	N/A
SRPT Sarepta Therapeutics	2.00	Hold	$22.88	25.83% Upside

Current Analyst Ratings Breakdown

Latest SRPT, OPHLF, BHC, and IONS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/22/2026	IONS Ionis Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
10/22/2026	IONS Ionis Pharmaceuticals	BMO Capital Markets Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Market Perform ➝ Outperform	$54.00 ➝ $66.00
10/21/2026	IONS Ionis Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
10/20/2026	IONS Ionis Pharmaceuticals	Raymond James Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Set Price Target		$79.00
10/15/2026	IONS Ionis Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/15/2026	IONS Ionis Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Neutral ➝ Buy	$46.00 ➝ $88.00
10/13/2026	SRPT Sarepta Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
10/8/2026	BHC Bausch Health Cos	Royal Bank Of Canada Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sector Perform	$9.00
10/8/2026	SRPT Sarepta Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Sector Perform	$19.00 ➝ $17.00
10/5/2026	SRPT Sarepta Therapeutics	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Hold ➝ Strong Sell
10/5/2026	SRPT Sarepta Therapeutics	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell	$5.00

(Data available from 10/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BHC Bausch Health Cos	$10.27B	0.24	$7.29 per share	0.89	$1.02 per share	6.36
IONS Ionis Pharmaceuticals	$944M	7.73	N/A	N/A	$3.02 per share	14.54
OPHLF Ono Pharmaceutical	$3.43B	2.08	$1.49 per share	10.19	$11.39 per share	1.33
SRPT Sarepta Therapeutics	$2.20B	0.87	N/A	N/A	$10.89 per share	1.67

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BHC Bausch Health Cos	$157M	-$2.96	N/A	1.61	N/A	-10.12%	-561.95%	6.31%	10/28/2026 (Estimated)
IONS Ionis Pharmaceuticals	-$381.39M	-$3.46	N/A	N/A	N/A	-64.76%	-111.08%	-17.41%	11/4/2026 (Estimated)
OPHLF Ono Pharmaceutical	$436.04M	$1.05	13.42	N/A	N/A	15.02%	9.77%	7.63%	10/28/2026 (Estimated)
SRPT Sarepta Therapeutics	-$713.41M	-$2.90	N/A	13.57	0.34	-13.48%	-1.60%	-0.66%	11/5/2026 (Confirmed)

Latest SRPT, OPHLF, BHC, and IONS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/4/2026	Q3 2026	IONS Ionis Pharmaceuticals	-$1.22	N/A	N/A	N/A	$181.56 million	N/A
11/2/2026	Q3 2026	SRPT Sarepta Therapeutics	$0.0740	N/A	N/A	N/A	$352.20 million	N/A
10/28/2026	Q3 2026	BHC Bausch Health Cos	$1.25	N/A	N/A	N/A	$2.72 billion	N/A
10/28/2026	N/A	OPHLF Ono Pharmaceutical	$0.26	N/A	N/A	N/A	$728.39 million	N/A
8/5/2026	Q2 2026	SRPT Sarepta Therapeutics	$0.2173	$0.64	+$0.4227	-$0.05	$366.39 million	$401.25 million
7/29/2026	Q2 2026	BHC Bausch Health Cos	$0.96	$1.26	+$0.30	$0.68	$2.59 billion	$2.83 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BHC Bausch Health Cos	N/A	N/A	N/A	N/A	N/A
IONS Ionis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
OPHLF Ono Pharmaceutical	N/A	N/A	N/A	N/A	N/A
SRPT Sarepta Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BHC Bausch Health Cos	N/A	1.44	1.08
IONS Ionis Pharmaceuticals	3.07	7.89	7.73
OPHLF Ono Pharmaceutical	0.08	3.28	2.86
SRPT Sarepta Therapeutics	0.55	4.42	2.62

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BHC Bausch Health Cos	78.65%
IONS Ionis Pharmaceuticals	93.86%
OPHLF Ono Pharmaceutical	N/A
SRPT Sarepta Therapeutics	86.68%

Insider Ownership

Company	Insider Ownership
BHC Bausch Health Cos	20.67%
IONS Ionis Pharmaceuticals	1.81%
OPHLF Ono Pharmaceutical	N/A
SRPT Sarepta Therapeutics	6.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BHC Bausch Health Cos	20,300	374.38 million	297.00 million	Optionable
IONS Ionis Pharmaceuticals	1,402	166.18 million	163.18 million	Optionable
OPHLF Ono Pharmaceutical	4,206	469.91 million	N/A	Not Optionable
SRPT Sarepta Therapeutics	835	105.63 million	98.34 million	Optionable

SRPT, OPHLF, BHC, and IONS Headlines

Recent News About These Companies

Sarepta Therapeutics (SRPT) Receives a Rating Update from a Top Analyst

4 hours ago | theglobeandmail.com

Sarepta Therapeutics to Announce Third Quarter 2026 Financial Results

October 22 at 9:00 AM | businesswire.com

Analysts Offer Insights on Healthcare Companies: Definium Therapeutics (DFTX), Sarepta Therapeutics (SRPT) and BioNTech SE (BNTX)

October 20 at 2:16 PM | theglobeandmail.com

Sarepta Therapeutics (NASDAQ:SRPT) Shares Up 8.2% - Time to Buy?

October 20 at 1:19 PM | marketbeat.com

H.C. Wainwright keeps USD 5 target for Sarepta Therapeutics stock

October 20 at 9:15 AM | ad-hoc-news.deA

Sarepta Therapeutics, Inc. (SRPT) Stock Analysis: Navigating a 26.53% Potential Upside Amidst Biotechnology Challenges

October 19, 2026 | directorstalkinterviews.com

Cartesian Therapeutics (NASDAQ:RNAC) and Sarepta Therapeutics (NASDAQ:SRPT) Head to Head Contrast

October 19, 2026 | americanbankingnews.com

Sarepta presents 80 percent DM1 data for Sarepta Therapeutics stock

October 18, 2026 | ad-hoc-news.deA

What Is The Case For Waiting On Moderna Stock?

October 17, 2026 | trefis.comT

Leerink Partners Reaffirms Their Hold Rating on Sarepta Therapeutics (SRPT)

October 16, 2026 | theglobeandmail.com

Sarepta Therapeutics Faces New Growth Opportunity Emerging From SiRNA Programs, Wedbush Says

October 16, 2026 | finance.yahoo.com

Sarepta Therapeutics: Buy Rating Reiterated on Expanding RNA Pipeline; Price Target Maintained at $35

October 16, 2026 | tipranks.com

Sarepta Therapeutics, Inc. Presents New Preclinical Data Demonstrating Robust Knockdown Of Pathogenic DMPK RNA In The Nucleus With SRP-1003 In DM1 At 2026 Oligonucleotide ...

October 15, 2026 | marketscreener.comM

Sarepta Therapeutics Presents New Preclinical Data Demonstrating Robust Knockdown of Pathogenic DMPK RNA in the Nucleus with SRP-1003 in DM1 at 2026 Oligonucleotide ...

October 15, 2026 | marketscreener.comM

Sarepta Therapeutics Presents New Preclinical Data Demonstrating Robust Knockdown of Pathogenic DMPK RNA in the Nucleus with SRP-1003 in DM1 at 2026 Oligonucleotide Therapeutics Society Annual Meeting

October 14, 2026 | finance.yahoo.com

October 14, 2026 | businesswire.com

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Stock Has Consensus Price Target of $22.59 According to Brokerages

October 13, 2026 | americanbankingnews.com

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Stock Has Average Target Price of $22.59

October 13, 2026 | marketbeat.com

Global Capsid Tropism Screening Platforms Market Report 2026 | Capitalize on 14.4% CAGR to $1.45B by 2030 as Sarepta, Voyager, REGENXBIO and Dyno Scale AI and NGS Screening

October 12, 2026 | finance.yahoo.com

Bank of America Securities Reaffirms Their Sell Rating on Sarepta Therapeutics (SRPT)

October 10, 2026 | theglobeandmail.com

RBC Cuts Price Target on Sarepta Therapeutics to $17 From $19, Keeps Sector Perform, Speculative Risk

October 8, 2026 | marketscreener.comM

New MarketBeat Followers Over Time

Media Sentiment Over Time

SRPT, OPHLF, BHC, and IONS Company Descriptions

Bausch Health Cos NYSE:BHC

$6.48 +0.04 (+0.54%)

Closing price 10/22/2026 03:59 PM Eastern

Extended Trading

$6.48 0.00 (-0.08%)

As of 04:24 AM Eastern

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

Ionis Pharmaceuticals NASDAQ:IONS

$43.91 -0.36 (-0.81%)

Closing price 10/22/2026 04:00 PM Eastern

Extended Trading

$43.90 -0.01 (-0.03%)

As of 04:37 AM Eastern

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.

Ono Pharmaceutical OTCMKTS:OPHLF

$15.16 0.00 (0.00%)

As of 10/21/2026

Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo Intravenous Infusion and Kyprolis Intravenous Injection for malignant tumors; Emend capsules/Proemend intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; and Mektovi, Velexbru, and Braftovi capsules for malignant tumors, as well as ADLUMIZ tablets for cancer cachexia. The company also provides Glactiv tablets for type 2 diabetes; Forxiga tablets for diabetes; Onoact Intravenous Infusion for tachyarrhythmia; Opalmon tablets to treat peripheral circulatory disorder; Coralan for chronic heart failure; Orencia injections for rheumatoid arthritis; Rivastach patches for Alzheimer's disease; Ongentys tablets for Parkinson's disease; Parsabiv, an intravenous infusion for dialysis patients; Staybla tablets for overactive bladder; Onon capsules and Dry Syrups for bronchial asthma and allergic rhinitis; and JOYCLU intra-articular injection for the improvement of joint function, as well as Recalbon tablets for osteoporosis. In addition, it develops products for hepatocellular and urothelial carcinoma; ovarian, bladder, prostate, pancreatic, gastric, esophageal, colorectal, thyroid, cell lung, and breast cancer; acute myeloid leukemia; solid tumors; myelodysplastic syndrome; melanoma; T-cell lymphoma; tachyarrhythmia; pemphigus; scleroderma; seizures; diabetic polyneuropathy; neurodegenerative diseases; autoimmune diseases; narcolepsy; and thrombosis. The company has a collaboration with Adimab, LLC to discover novel antibody drugs; a research collaboration with Turbine Ltd. to identify and validate novel oncology targets; Harvard University for validating novel therapeutic targets; and a strategic drug discovery collaboration with Sibylla Biotech in central nervous system disorders. The company was founded in 1717 and is headquartered in Osaka, Japan.

Sarepta Therapeutics NASDAQ:SRPT

$18.18 -0.38 (-2.05%)

Closing price 10/22/2026 04:00 PM Eastern

Extended Trading

$18.12 -0.05 (-0.30%)

As of 04:01 AM Eastern

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SRPT, OPHLF, BHC, and IONS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SRPT, OPHLF, BHC, and IONS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SRPT, OPHLF, BHC, and IONS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SRPT, OPHLF, BHC, and IONS Company Descriptions

Bausch Health Cos NYSE:BHC

Ionis Pharmaceuticals NASDAQ:IONS

Ono Pharmaceutical OTCMKTS:OPHLF

Sarepta Therapeutics NASDAQ:SRPT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SRPT, OPHLF, BHC, and IONS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SRPT, OPHLF, BHC, and IONS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SRPT, OPHLF, BHC, and IONS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SRPT, OPHLF, BHC, and IONS Company Descriptions

Bausch Health Cos NYSE:BHC

Ionis Pharmaceuticals NASDAQ:IONS

Ono Pharmaceutical OTCMKTS:OPHLF

Sarepta Therapeutics NASDAQ:SRPT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools